Advertisement

Mechanism for the Development of Bone Disease in Diabetes: Renal Bone Disease

  • Yasuo ImanishiEmail author
  • Masaaki Inaba
Chapter

Abstract

Bone fragility is caused by chronic kidney disease (CKD). Renal osteodystrophy induced by secondary hyperparathyroidism of uremia is considered the main factor for the bone disease. Meanwhile, studies on degeneration of bone quality in CKD have recently advanced, and development of diagnostic and treatment methods is awaited.

Keywords

Osteoporosis Chronic kidney disease (CKD) Chronic kidney disease-mineral and bone disease (CKD-MBD) Bone quality 

References

  1. 1.
    NIH Consensus Development Panel on Osteoporosis Prevention D, Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6):785–795CrossRefGoogle Scholar
  2. 2.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351(13):1296–1305. doi: 10.1056/NEJMoa041031 CrossRefPubMedGoogle Scholar
  3. 3.
    Goldsmith D, Kothawala P, Chalian A, Bernal M, Robbins S, Covic A (2009) Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of fracture and need for parathyroidectomy in CKD. Am J Kidney Dis 53(6):1002–1013. doi: 10.1053/j.ajkd.2009.02.010 CrossRefPubMedGoogle Scholar
  4. 4.
    Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D (2009) Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 24(5):1506–1523. doi: 10.1093/ndt/gfn613 CrossRefPubMedGoogle Scholar
  5. 5.
    Miller PD (2014) Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am J Kidney Dis 64(2):290–304. doi: 10.1053/j.ajkd.2013.12.018 CrossRefPubMedGoogle Scholar
  6. 6.
    Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69(11):1945–1953. doi: 10.1038/sj.ki.5000414 CrossRefPubMedGoogle Scholar
  7. 7.
    Fujita Y, Iki M, Tamaki J, Kouda K, Yura A, Kadowaki E, Sato Y, Moon JS, Tomioka K, Okamoto N, Kurumatani N (2013) Renal function and bone mineral density in community-dwelling elderly Japanese men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study. Bone 56(1):61–66. doi: 10.1016/j.bone.2013.05.004 CrossRefPubMedGoogle Scholar
  8. 8.
    Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR (2007) Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22(4):503–508. doi: 10.1359/jbmr.070112 CrossRefPubMedGoogle Scholar
  9. 9.
    Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C (2000) Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58(1):396–399. doi: 10.1046/j.1523-1755.2000.00178.x CrossRefPubMedGoogle Scholar
  10. 10.
    Ensrud KE, Lui LY, Taylor BC, Ishani A, Shlipak MG, Stone KL, Cauley JA, Jamal SA, Antoniucci DM, Cummings SR, Osteoporotic Fractures Research G (2007) Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 167(2):133–139. doi: 10.1001/archinte.167.2.133 CrossRefPubMedGoogle Scholar
  11. 11.
    Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer ES, Ensrud KE, Donaldson MG, Cauley JA, Harris TB, Koster A, Womack CR, Palermo L, Black DM, Study of Osteoporotic Fractures Research Group, Osteoporotic Fractures in Men Research Group, Health Aging and Body Composition Research Group (2011) Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305(21):2184–2192. doi: 10.1001/jama.2011.715
  12. 12.
    Nickolas TL, McMahon DJ, Shane E (2006) Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 17(11):3223–3232. doi: 10.1681/ASN.2005111194 CrossRefPubMedGoogle Scholar
  13. 13.
    Wakasugi M, Kazama JJ, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Narita I (2013) Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Miner Metab 31(3):315–321. doi: 10.1007/s00774-012-0411-z CrossRefPubMedGoogle Scholar
  14. 14.
    Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard M, Ott S, Rodriguez M, Stehman-Breen C, Stern P, Weisinger J, Osteoporosis Work G (2004) Osteoporosis in chronic kidney disease. Am J Kidney Dis 43(3):566–571CrossRefPubMedGoogle Scholar
  15. 15.
    Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH (2011) Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 6(4):877–882. doi: 10.2215/CJN.06550810 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (113):S1–130Google Scholar
  17. 17.
    Saito M, Marumo K (2010) Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 21(2):195–214. doi: 10.1007/s00198-009-1066-z CrossRefPubMedGoogle Scholar
  18. 18.
    Saito M, Marumo K, Soshi S, Kida Y, Ushiku C, Shinohara A (2010) Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. Osteoporos Int 21(4):655–666. doi: 10.1007/s00198-009-0980-4 CrossRefPubMedGoogle Scholar
  19. 19.
    Mitome J, Yamamoto H, Saito M, Yokoyama K, Marumo K, Hosoya T (2011) Nonenzymatic cross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patients. Calcif Tissue Int 88(6):521–529. doi: 10.1007/s00223-011-9488-y CrossRefPubMedGoogle Scholar
  20. 20.
    Patsch JM, Burghardt AJ, Yap SP, Baum T, Schwartz AV, Joseph GB, Link TM (2013) Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res 28(2):313–324. doi: 10.1002/jbmr.1763 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Nickolas TL, Stein EM, Dworakowski E, Nishiyama KK, Komandah-Kosseh M, Zhang CA, McMahon DJ, Liu XS, Boutroy S, Cremers S, Shane E (2013) Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res 28(8):1811–1820. doi: 10.1002/jbmr.1916 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Ambrus C, Almasi C, Berta K, Deak G, Marton A, Molnar MZ, Nemeth Z, Horvath C, Lakatos P, Szathmari M, Mucsi I (2011) Vitamin D insufficiency and bone fractures in patients on maintenance hemodialysis. Int Urol Nephrol 43(2):475–482. doi: 10.1007/s11255-010-9723-x CrossRefPubMedGoogle Scholar
  23. 23.
    Looker AC, Mussolino ME (2008) Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. J Bone Miner Res 23(1):143–150. doi: 10.1359/jbmr.071003 CrossRefPubMedGoogle Scholar
  24. 24.
    Imanishi Y, Inaba M, Kawata T, Nishizawa Y (2009) Animal models of hyperfunctioning parathyroid diseases for drug development. Expert Opin Drug Discov 4(7):727–740CrossRefPubMedGoogle Scholar
  25. 25.
    Imanishi Y, Nishizawa Y, Inaba M (2013) Chapter 5: Pathogenesis and treatment of chronic kidney disease-mineral and bone disorder. In: Suzuki H (ed) Hemodialysis. InTech, Rijeka, pp 81–100Google Scholar
  26. 26.
    Kawata T, Imanishi Y, Kobayashi K, Onoda N, Okuno S, Takemoto Y, Komo T, Tahara H, Wada M, Nagano N, Ishimura E, Miki T, Ishikawa T, Inaba M, Nishizawa Y (2006) Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. J Bone Miner Metab 24(4):300–306. doi: 10.1007/s00774-006-0687-y CrossRefPubMedGoogle Scholar
  27. 27.
    Nechama M, Ben-Dov IZ, Silver J, Naveh-Many T (2009) Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD. Am J Physiol Ren Physiol 296(4):F795–F800. doi: 10.1152/ajprenal.90625.2008 CrossRefGoogle Scholar
  28. 28.
    Imanishi Y, Kawata T, Kenko T, Wada M, Nagano N, Miki T, Arnold A, Inaba M (2011) Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism. Calcif Tissue Int 89(1):29–35. doi: 10.1007/s00223-011-9490-4 CrossRefPubMedGoogle Scholar
  29. 29.
    Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI (1997) Mutation of the mouse klotho gene leads to a syndrome resembling aging. Nature 390(6655):45–51. doi: 10.1038/36285 CrossRefPubMedGoogle Scholar
  30. 30.
    Kim HR, Nam BY, Kim DW, Kang MW, Han JH, Lee MJ, Shin DH, Doh FM, Koo HM, Ko KI, Kim CH, Oh HJ, Yoo TH, Kang SW, Han DS, Han SH (2013) Circulating alpha-klotho levels in CKD and relationship to progression. Am J Kidney Dis 61(6):899–909. doi: 10.1053/j.ajkd.2013.01.024 CrossRefPubMedGoogle Scholar
  31. 31.
    Imanishi Y, Tahara H, Palanisamy N, Spitalny S, Salusky IB, Goodman W, Brandi ML, Drueke TB, Sarfati E, Urena P, Chaganti RS, Arnold A (2002) Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. J Am Soc Nephrol 13(6):1490–1498CrossRefPubMedGoogle Scholar
  32. 32.
    Tokumoto M, Tsuruya K, Fukuda K, Kanai H, Kuroki S, Hirakata H (2002) Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int 62(4):1196–1207. doi: 10.1111/j.1523-1755.2002.kid585.x CrossRefPubMedGoogle Scholar
  33. 33.
    Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, Drueke TB (1997) Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 51(1):328–336CrossRefPubMedGoogle Scholar
  34. 34.
    Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y (2004) FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65(5):1943–1946. doi: 10.1111/j.1523-1755.2004.00604.x CrossRefPubMedGoogle Scholar
  35. 35.
    Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, Tominaga Y, Otsuki N, Nibu K, Nakagawa K, Tsugawa N, Okano T, Kitazawa R, Fukagawa M, Kita T (2010) Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77(3):232–238. doi: 10.1038/ki.2009.414 CrossRefPubMedGoogle Scholar
  36. 36.
    Mirza MA, Karlsson MK, Mellstrom D, Orwoll E, Ohlsson C, Ljunggren O, Larsson TE (2011) Serum fibroblast growth factor 23 (FGF-23) and fracture risk in elderly men. J Bone Miner Res 26(4):857–864. doi: 10.1002/jbmr.263 CrossRefPubMedGoogle Scholar
  37. 37.
    Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348(17):1656–1663. doi: 10.1056/NEJMoa020881 CrossRefPubMedGoogle Scholar
  38. 38.
    Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, Aubin JE, Maeda N (2008) Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 23(6):939–948. doi: 10.1359/jbmr.080220 CrossRefPubMedGoogle Scholar
  39. 39.
    Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y (2007) Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 18(10):2683–2688. doi: 10.1681/ASN.2006070783 CrossRefPubMedGoogle Scholar
  40. 40.
    Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20(12):2105–2115. doi: 10.1359/JBMR.050817 CrossRefPubMedGoogle Scholar
  41. 41.
    Wetmore JB, Benet LZ, Kleinstuck D, Frassetto L (2005) Effects of short-term alendronate on bone mineral density in hemodialysis patients. Nephrology 10(4):393–399. doi: 10.1111/j.1440-1797.2005.00436.x CrossRefPubMedGoogle Scholar
  42. 42.
    Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang YC, Egbuna OI, Boonen S, Miller PD (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26(8):1829–1835. doi: 10.1002/jbmr.403 CrossRefPubMedGoogle Scholar
  43. 43.
    Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27(7):1471–1479. doi: 10.1002/jbmr.1613 CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R, Mulitple Outcomes of Raloxifene Evaluation I (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87(8):3609–3617CrossRefPubMedGoogle Scholar
  45. 45.
    Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE, Investigators M (2008) The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 19(7):1430–1438. doi: 10.1681/ASN.2007050555 CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Adami S, Palacios S, Rizzoli R, Levine AB, Sutradhar S, Chines AA (2014) The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status. Climacteric 17(3):273–284. doi: 10.3109/13697137.2013.830605 CrossRefPubMedGoogle Scholar
  47. 47.
    Hernandez E, Valera R, Alonzo E, Bajares-Lilue M, Carlini R, Capriles F, Martinis R, Bellorin-Font E, Weisinger JR (2003) Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 63(6):2269–2274. doi: 10.1046/j.1523-1755.2003.00005.x CrossRefPubMedGoogle Scholar
  48. 48.
    Saito O, Saito T, Asakura S, Akimoto T, Inoue M, Ando Y, Muto S, Kusano E (2012) Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes. Int J Endocrinol Metab 10(2):464–469. doi: 10.5812/ijem.3794 CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH (2007) Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18(1):59–68. doi: 10.1007/s00198-006-0189-8 CrossRefPubMedGoogle Scholar
  50. 50.
    Gordon PL, Frassetto LA (2010) Management of osteoporosis in CKD Stages 3 to 5. Am J Kidney Dis 55(5):941–956. doi: 10.1053/j.ajkd.2010.02.338 CrossRefPubMedGoogle Scholar
  51. 51.
    Cejka D, Haas M (2011) Should teriparatide ever be used for adynamic bone disease? Semin Dial 24(4):431–433. doi: 10.1111/j.1525-139X.2011.00911.x CrossRefPubMedGoogle Scholar
  52. 52.
    Goto S, Fujii H, Hamada Y, Yoshiya K, Fukagawa M (2010) Association between indoxyl sulfate and skeletal resistance in hemodialysis patients. Ther Apher Dial 14(4):417–423. doi: 10.1111/j.1744-9987.2010.00813.x CrossRefPubMedGoogle Scholar
  53. 53.
    Hammerland LG, Garrett JE, Hung BC, Levinthal C, Nemeth EF (1998) Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 53(6):1083–1088PubMedGoogle Scholar
  54. 54.
    Kawata T, Imanishi Y, Kobayashi K, Kenko T, Wada M, Ishimura E, Miki T, Nagano N, Inaba M, Arnold A, Nishizawa Y (2005) Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism. Eur J Endocrinol 153(4):587–594. doi: 10.1530/eje.1.02007 CrossRefPubMedGoogle Scholar
  55. 55.
    Cunningham J, Danese M, Olson K, Klassen P, Chertow GM (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68(4):1793–1800. doi: 10.1111/j.1523-1755.2005.00596 CrossRefPubMedGoogle Scholar
  56. 56.
    Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Drueke TB, for the Evaluation of Cinacalcet HTtL CETI (2015) Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE Trial. J Am Soc Nephrol. doi: 10.1681/ASN.2014040414 PubMedCentralGoogle Scholar
  57. 57.
    Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B (2007) Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 18(8):2401–2407. doi: 10.1681/ASN.2007010022 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2016

Authors and Affiliations

  1. 1.Department of Metabolism, Endocrinology, and Molecular MedicineOsaka City University Graduate School of MedicineOsakaJapan

Personalised recommendations